- https://ecog-acrin.org
- https://www.facebook.com/eaonc/
- https://www.linkedin.com/company/5315198/
- https://twitter.com/eaonc
- http://www.ecog.org
- https://www.youtube.com/channel/UCAC_V1QdqlH2KdHOt7K2IHw
- https://ecog-acrin.org/
- https://ecog-acrin.org/about-us
- https://ecog-acrin.org/about-us/organizational-overview
- https://ecog-acrin.org/about-us/ecog-acrin-leadership
- https://ecog-acrin.org/about-us/governance
- https://ecog-acrin.org/about-us/membership
- https://ecog-acrin.org/about-us/scientific-planning-and-review
- https://ecog-acrin.org/about-us/trial-monitoring
- https://ecog-acrin.org/about-us/operations
- https://ecog-acrin.org/about-us/biostatistics-and-data-management
- https://ecog-acrin.org/about-us/collaborations
- https://ecog-acrin.org/clinical-trials
- https://ecog-acrin.org/participating-institutions
- https://ecog-acrin.org/about-us/scientific-achievements
- https://ecog-acrin.org/about-us/constitution
- https://ecog-acrin.org/scientific_programs
- https://ecog-acrin.org/scientific_programs/cancer-control-and-outcomes
- https://ecog-acrin.org/scientific_programs/therapeutic-studies
- https://ecog-acrin.org/scientific_programs/biomarker-sciences
- https://ecog-acrin.org/research-support
- https://ecog-acrin.org/research-support/research-support-committees
- https://ecog-acrin.org/research-support/mentorship
- https://ecog-acrin.org/research-support/training-and-education
- https://ecog-acrin.org/research-cores
- https://ecog-acrin.org/research-cores/central-biorepository-and-pathology-facility
- https://ecog-acrin.org/research-cores/imaging-core-laboratory
- https://ecog-acrin.org/research-cores/leukemia-integrated-translational-science-center
- https://ecog-acrin.org/research-cores/thoracic-malignancies-integrated-translational-science-center
- https://ecog-acrin.org/resources
- https://ecog-acrin.org/resources/group-meetings
- https://ecog-acrin.org/resources/educational-materials
- https://ecog-acrin.org/nci-match-eay131-researchers
- https://ecog-acrin.org/resources/publications
- https://ecog-acrin.org/resources/ecog-performance-status
- https://ecog-acrin.org/resources/sample-tracking-system
- https://ecog-acrin.org/resources/nci-central-institutional-review-board
- https://ecog-acrin.org/resources/medidata-rave
- https://ecog-acrin.org/resources/triad
- https://ecog-acrin.org/resources/soapp
- https://ecog-acrin.org/resources/precog
- https://ecog-acrin.org/resources/related-websites
- https://ecog-acrin.org/resources/documents-and-photos
- https://ecog-acrin.org/patients
- https://ecog-acrin.org/patients/myths-and-facts
- https://ecog-acrin.org/patients/resources
- https://ecog-acrin.org/news-and-info
- https://ecog-acrin.org/news-and-info/announcements
- https://ecog-acrin.org/news-and-info/newsletters
- https://ecog-acrin.org/news-and-info/press-releases
- https://ecog-acrin.org/contact-us
- https://ecog-acrin.org/contact-us/donations
- https://ecog-acrin.org/contact-us/locations
- https://ecog-acrin.org/office-of-communications
- https://ecog-acrin.org/about-us/governance/principal-investigator-committee
- https://ecog-acrin.org/research-support/research-support-committees-cra
- https://ecog-acrin.org/research-support/mentorship/young-investigator-symposium
- https://ecog-acrin.org/announcements/rfp-for-combomatch-subprotocol-concepts
- https://acr.informz.net/informzdataservice/onlineversion/ind/bWFpbGluZ2luc3RhbmNlaWQ9NzUxMjQ1NSZzdWJzY3JpYmVyaWQ9OTI4NTI4MDU4
- https://ecog-acrin.org/news-and-info/press-releases/ibrutiniib-rituximab-superior-to-standard-treatment-for-younger-cll-patients
- https://ecog-acrin.org/news-and-info/press-releases/surgical-planning-for-head-and-neck-cancer-benefits-from-fdg-pet-ct-acrin-6685-results
- https://www.sabcs.org/2019-SABCS-sup-sup-/Blogs/ArticleID/170/SABCS-awards-Joseph-A-Sparano-the-William-L-McGuire-Memorial-Lecture-Award
- https://cancerletter.com/articles/20190712_6/
- https://www.cancernetwork.com/news/asco-updates-guidelines-early-breast-cancer-based-tailorx-mindact-trials
- https://ecog-acrin.org/news-and-info/press-releases/tailorx-clinical-and-genomic-risk-integration-nejm-asco
- https://www.nejm.org/doi/full/10.1056/NEJMoa1904819
- https://www.nejm.org/doi/full/10.1056/NEJMe1906088?query=recirc_curatedRelated_article
- https://www.prnewswire.com/news-releases/updated-asco-guidelines-establish-tailorx-defined-cutoffs-for-determining-chemotherapy-benefit-with-the-oncotype-dx-breast-recurrence-score-test-in-node-negative-breast-cancer-300860341.html
- https://www.genomeweb.com/cancer/one-year-post-tailorx-attitudes-shift-and-questions-linger-breast-cancer-recurrence-testing#.XPlkaq-B7ct
- https://www.cancernetwork.com/asco/using-genomic-profiling-guide-treatment-decisions-er-positive-breast-cancers
- https://www.ascopost.com/News/60141
- https://ecog-acrin.org/news-and-info/press-releases/nci-match-trial-finding-at-asco-2019
- https://xconomy.com/national/2018/05/31/drugs-okd-to-hit-tumor-genes-still-a-basket-of-one-are-more-coming/
- https://ecog-acrin.org/news-and-info/press-releases/ea2810-results-released-at-2019-asco-meeting
- https://www.urotoday.com/conference-highlights/asco-2019-annual-meeting/asco-2019-kidney-cancer/113034-asco-2019-randomized-double-blind-phase-iii-study-of-pazopanib-versus-placebo-in-patients-with-metastatic-renal-cell-carcinoma-who-have-no-evidence-of-disease-following-metastasectomy-medical-oncologist-perspective.html
- https://medicalxpress.com/news/2019-06-benefit-pazopanib-advanced-kidney-cancer.html
- https://www.asco.org/about-asco/press-center/news-releases/lenalidomide-reduces-risk-precancer-myeloma-will-progress
- https://dailynews.ascopubs.org/do/10.1200/ADN.19.190348/full/?cid=DM2352&bid=18268612
- https://ncorp.cancer.gov
- http://www.cancer.gov/research/areas/clinical-trials/nctn
- https://ecog-acrin.org/active-clinical-trials
- https://ecog-acrin.org/about-us/participating-institutions
- https://ecog-acrin.org/nci-match-eay131
- https://ecog-acrin.org/tmist
- http://ecogacrin.wpengine.com/about-us/disclaimer
Thursday, September 5, 2019
Home - ECOG-ACRIN
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment